Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.45 |
| ▸ | MEN1 | O00255 | 4/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | GAA | P10253 | 4/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | TLR4 | O00206 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MGAM | O43451 | 1/20 | 0.34 |
| ▸ | SI | P14410 | 1/20 | 0.34 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4944675 | 0.83 | ALDH1A1 (0.36) | ALDH1A1MEN1KMT2AGAAHSD17B10 | |
| SCHEMBL8489133 | 0.83 | ALDH1A1 (0.43) | ALDH1A1MEN1KMT2AGAAHSD17B10 | |
| SCHEMBL9793537 | 0.83 | ALDH1A1 (0.46) | ALDH1A1MEN1KMT2AGAAHSD17B10 | |
| SCHEMBL189981 | 0.79 | KMT2A (0.38) | ALDH1A1KMT2AHSD17B10HPGDKDM4E | |
| SCHEMBL3196831 | 0.75 | ALDH1A1 (0.56) | ALDH1A1MEN1KMT2AGAAHSD17B10 | |
| SCHEMBL11198763 | 0.72 | ALDH1A1 (0.39) | ALDH1A1MEN1KMT2AGAAHSD17B10 | |
| SCHEMBL9877944 | 0.72 | KDM4E (0.38) | ALDH1A1MEN1KMT2AGAAHSD17B10 | |
| SCHEMBL1134463 | 0.72 | ALDH1A1 (0.53) | ALDH1A1MEN1KMT2AGAAHSD17B10 | |
| SCHEMBL1846269 | 0.71 | ALDH1A1 (0.45) | ALDH1A1MEN1KMT2AGAAHSD17B10 | |
| SCHEMBL4080364 | 0.71 | ALDH1A1 (0.51) | ALDH1A1MEN1KMT2AGAAHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9303040-B2 | Substituted piperazines as AKT inhibitors | ARRAY BIOPHARMA INC. (US) | 2016-04-05 | — | — | US | disclosed |
| US-20120329808-A1 | DIHYDROTHIENO PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2012-12-27 | — | — | US | disclosed |
| EP-1663994-B1 | TETRAHYDROQUINAZOLINE COMPOUNDS AS INHIBITORS OF VOLTAGE-GATED ION CHANNELS | VERTEX PHARMA (US) | 2012-03-07 | — | — | EP | disclosed |
| US-20120040935-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF VOLTAGE-GATED ION CHANNELS | VERTEX PHARMACEUTICALS, INC. (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120040935-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF VOLTAGE-GATED ION CHANNELS | VERTEX PHARMACEUTICALS, INC. (US) | 2012-02-16 | — | — | US | disclosed |
| EP-2054418-B1 | DIHYDROTHIENO PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2011-11-09 | — | — | EP | disclosed |
| US-7968545-B2 | Compositions useful as inhibitors of voltage-gated ion channels | VERTEX PHARMACEUTICALS INC. (US) | 2011-06-28 | — | — | US | disclosed |
| US-7947690-B2 | Insulin secretagogue and hypoglycemic agent; pyrimidine derivatives condensed with a non-aromatic ring selected from dihydrothiophene, dihydrofuran, cycloalkane moiety; 1-[2-(4-chloro-2,5-difluorophenyl)-6,6-dioxido-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl]-4-(3-hydroxypropyl)piperidin-4-ol for example | ASTELLAS PHARMA INC. (JP) | 2011-05-24 | — | — | US | disclosed |
| EP-2054418-A1 | DIHYDROTHIENO PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2009-05-06 | — | — | EP | disclosed |
| US-20080070896-A1 | Pyrimidine Derivative Condensed with a Non-Aromatic Ring | ASTELLAS PHARMA INC. (JP) | 2008-03-20 | — | — | US | disclosed |
| WO-2008006039-A1 | DIHYDROTHIENO PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2008-01-10 | — | — | WO | disclosed |
| EP-1803710-A1 | PYRIMIDINE DERIVATIVE CONDENSED WITH NON-AROMATIC RING | Astellas Pharma Inc. (JP) | 2007-07-04 | — | — | EP | disclosed |
| WO-2005014558-A1 | CONDENSED PYRAMIDINE COMPOUNDS AS INHIBITORS OF VOLTAGE-GATED ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-02-17 | — | — | WO | disclosed |
| EP-0344983-B1 | PROCESS FOR PREPARING 2- AND 4-ALKOXYCARBONYL THIOLAN-3-ONES | JOHN WYETH & BROTHER LIMITED (GB) | 1993-09-15 | — | — | EP | disclosed |
| EP-0344983-A1 | Process for preparing 2- and 4-alkoxycarbonyl thiolan-3-ones | JOHN WYETH & BROTHER LIMITED (GB) | 1989-12-06 | — | — | EP | disclosed |
| US-4437878-A | Dihydrothiophenecarboxylates and their use for controlling undersirable plant growth | BASF AKTIENGESELLSCHAFT (DE) | 1984-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040935-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF VOLTAGE-GATED ION CHANNELS | KCNQ1, KCNN2, KCNH3 | ALDH1A1 3086/4885MEN1 2441/4885KMT2A 3069/4885 |
| US-20080070896-A1 | Pyrimidine Derivative Condensed with a Non-Aromatic Ring | GPR119, IRS1, NONO | ALDH1A1 1052/4885MEN1 4155/4885KMT2A 2311/4885 |
| US-20120329808-A1 | DIHYDROTHIENO PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | DTYMK, TK1, PIK3CA | ALDH1A1 3262/4885MEN1 3082/4885KMT2A 1909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.